null - FindTrial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224595

Enrollment

1037

Registered

2019-03-14

Start date

2019-03-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : Talazoparib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational mater

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
confirmatory efficacy	—

Secondary

Measure	Time frame
safety efficacy confirmatory exploratory pharmacokinetics	—

Countries

Africa, Asia except Japan, Europe, Japan, North America, Oceania, South America

Outcome results